MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202641084307 A) filed by Dr. Shaik Harun Rasheed; Yerra Ashwini; Shaik Zareena Begum; Dr. Harikiran Lingabathula; Dr. Mandepudi Lakshmi Chandini; Dr. S. Naazneen; Dr. Praveen N. Khatale; Dr. Snehal S. Manekar; Manisha P. More; and Sneha B. Gaurkar on July 09, 2026, for A Novel Stability-Indicating Rp-Hplc Method For The Simultaneous Estimation Of Hydrochlorothiazide And Valsartan In Bulk Drugs And Pharmaceutical Dosage Forms.
Inventors include Dr. Shaik Harun Rasheed; Yerra Ashwini; Shaik Zareena Begum; Dr. Harikiran Lingabathula; Dr. Mandepudi Lakshmi Chandini; Dr. S. Naazneen; Dr. Praveen N. Khatale; Dr. Snehal S. Manekar; Manisha P. More; and Sneha B. Gaurkar.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: The present invention relates to the field of pharmaceutical analytical chemistry and, more particularly, to a novel reverse-phase high- performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of Hydrochlorothiazide and Valsartan in bulk drug substances and pharmaceutical dosage forms. The method employs a C18 chromatographic column with a mobile phase comprising methanol and phosphate buffer (pH 3.0) in the ratio of 70:30 (v/v), delivered at a flow rate of 1.0 mL/min with ultraviolet detection at 240 nm. Under the optimized chromatographic conditions, Hydrochlorothiazide and Valsartan are efficiently separated with retention times of approximately 2.17 minutes and 7.28 minutes, respectively, within a total run time of about 10 minutes. The developed analytical method is validated in accordance with International Council for Harmonisation (ICH) guidelines for specificity, linearity, accuracy, precision, robustness, limit of detection, limit of quantification, and system suitability. The invention provides a simple, rapid, accurate, precise, economical, and reproducible analytical method suitable for routine quality control, assay determination, stability studies, and regulatory analysis of Hydrochlorothiazide and Valsartan in pharmaceutical formulations. The disclosed method offers improved analytical performance, reduced analysis time, and reliable simultaneous quantification of both active pharmaceutical ingredients, thereby making it suitable for application in pharmaceutical industries, research laboratories, and quality control laboratories. Applicant(s) Dr. Harun Rasheed et. al.
Disclaimer: Curated by HT Syndication.
